Form 4: ADC Therapeutics Executive Receives RSU Award

ADC Therapeutics SA reports an RSU award to Chief Legal Officer Peter J. Graham, with vesting conditions tied to continued employment and employment status.

Summary

• Peter J. Graham, Chief Legal Officer of ADC Therapeutics SA, received an award of 221,100 Restricted Stock Units (RSUs) on June 30, 2026.
• These RSUs are contingent rights to receive one share of the Issuer's common stock.
• The RSUs are scheduled to vest on June 30, 2027, or earlier upon termination of employment by the Issuer without cause or by Mr. Graham for good reason, provided he is still employed on the vesting date.
• Following this award, Mr. Graham beneficially owns 841,640 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development.

Positives

• Grant of RSUs to a key executive, indicating continued investment in leadership and potential alignment of executive interests with shareholder value.
• The award is structured with vesting conditions that incentivize continued employment and performance.

Risks

• The value of the RSU award is subject to the future performance of ADC Therapeutics SA's stock price.
• Vesting is contingent on continued employment, meaning forfeiture is possible if employment is terminated under certain conditions.

Future Outlook

The RSU award is subject to vesting conditions, with a primary vesting date of June 30, 2027, or earlier under specific employment termination scenarios.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation in the biotechnology and pharmaceutical sectors, used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success of the company.

Stakeholder Impact

• Shareholders: The RSU award represents potential future dilution, but also aligns executive incentives with shareholder value creation.
• Employees: The award to a senior executive may reflect the company's strategy for retaining key talent.
• Management: Reinforces the compensation structure for senior leadership.

Next Steps

• Vesting of RSUs on or before June 30, 2027, contingent on employment status.
• Continued employment of Peter J. Graham as Chief Legal Officer.

Key Dates

Keywords

ADC Therapeutics SA, ADCT, Form 4, Restricted Stock Units, RSU Award, Executive Compensation, Peter J. Graham, Chief Legal Officer, Beneficial Ownership